

Effects of a Metabolic Nutritional Intervention Combined with Chemotherapy for Advanced Pancreatic Cancer

Poster Presented at ASCO GI Annual Meeting

SCOTTSDALE, ARIZONA, UNITED STATES, February 2, 2022 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of their phase II clinical trial in progress at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Annual Meeting in San Francisco, Calif., that was held Jan. 20-22.



The poster highlighted the latest advancements in treatments for pancreatic ductal adenocarcinoma (PDAC). PDAC tumors grow aggressively, and diagnosis is typically made after metastasis have occurred. The disease remains associated with poor outcomes. The triplet chemotherapy regimen of gemcitabine, nab-paclitaxel and cisplatin was associated with a median overall survival of 16.4 months in patients with metastatic pancreatic cancer in the first-line setting (Jameson et al., 2020). This poster described the randomized trial of a medically supervised ketogenic diet with the triplet chemotherapy regimen versus standard cancer diet plus triplet chemotherapy in patients with advanced pancreatic cancer. Unlike prior ketogenic intervention studies, patients in this trial are supported by a continuous care nutrition intervention. The trial includes tracking of daily ketone and glucose levels, a web-based

“

This trial could represent a cornerstone nutritional metabolic intervention in which rationally selected medicines could be added to improve outcomes for patients with pancreas cancer.”

*Dr. Stephen Gately, President
and CEO of TD2*

software application, education, and communication with a remote care team to ensure

sustained nutritional ketosis. The medically supervised ketogenic diet is defined as lower carbohydrate, lower protein, and higher fat. This can significantly reduce glucose and insulin and increase levels of metabolically active ketone bodies. Preclinically, a ketogenic diet combined with triplet chemotherapy was shown to inhibit KPC pancreatic tumor growth and significantly prolong animal survival compared to chemotherapy alone.

“TD2 focuses exclusively on oncology drug development and has long-standing experience conducting translational studies from bench-to-bedside against pancreatic cancer,” said Dr. Stephen Gately, President and CEO of TD2. “We are very excited to sponsor this trial and to offer a medically supervised ketogenic intervention to alter important metabolic factors known to be drivers of cancer growth. This trial could represent a cornerstone nutritional metabolic intervention in which rationally selected medicines could be added to improve outcomes for patients with pancreas cancer.”



Dr. Stephen Gately, President and CEO of TD2

Abstract TPS637: Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer (Friday, Jan. 21, 2022, 1:05 p.m. PST) Trials in Progress Poster Session B

The phase II trial is sponsored by TD2 with funding by Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

The trial opened for accrual in November 2020.

About TD

TD2 is a leader in precision oncology, providing innovative services for improved drug development. Using a dedicated, expert team with broad experience and understanding in cancer medicine, TD2 is uniquely positioned to support accelerated development of novel therapeutics. Rigorous and high-throughput translational preclinical development services, combined with regulatory affairs expertise, enables customized clinical trial design and execution. The broad suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process with the ultimate goal of accelerating patient access to promising

treatments. For more information, visit www.TD2inc.com.

Kristen Dempsey

Translational Drug Development (TD2)

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/561959491>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.